News

Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do more than produce a nice image on a slide. On the figures disclosed, the Cardiovalve TR System has made a credible case that it can.

Durability Is the Part That Gets Attention

TARGET enrolled 157 symptomatic patients with at least severe tricuspid regurgitation, with 148 receiving an implant. Their mean age was 78, 71% were women, 99% had secondary TR, and nearly 40% had torrential TR. This was no easy-patient parade. These were high-risk open-heart-surgery candidates, which makes both the clinical need and the safety bar painfully real.

The study met its 30-day performance endpoint: successful implantation with TR reduced to 2+ or less. More importantly, Venus says the reduction held up through three years, with 76.9% of patients reaching none or trace TR at that point. In structural-heart devices, durability is where plenty of early enthusiasm goes to die. A three-year signal is not a final verdict, but it is a lot more useful than a 30-day victory lap.

Patients Seem to Feel the Difference

The functional measures line up with the imaging outcome. At one year, the six-minute walk test improved by an average of 42 meters, while the Kansas City Cardiomyopathy Questionnaire score improved by 20 points. By three years, 80% of patients were classified as NYHA I or II, versus 39.9% at baseline. The company also reported reverse right-heart remodeling, including reductions in inferior vena cava diameter of 25%, mid-right-ventricular end-diastolic diameter of 22%, and basal RVEDD of 11%.

Those are encouraging readings because a device that merely alters a valve grade without helping a frail patient walk farther or function better has a commercial problem, plain and simple. Still, sensible observers should remember what TARGET is: a multicenter, prospective, single-arm, open-label study. There is no randomized control group in the disclosed material. The results deserve respect, not blind extrapolation against other therapies.

  • The three-year none-or-trace TR result is the headline durability figure.
  • The 42-meter walk improvement and 20-point KCCQ gain provide patient-centered support.
  • The lack of a stated comparator means relative performance remains an open question.

The Delivery-System Improvement May Matter Most

Safety is where this story turns from promising to genuinely worth watching. TARGET met its 30-day composite major-adverse-event endpoint under TVARC definitions. At 30 days, all-cause mortality was 5.7%, heart-failure rehospitalization was 1.9%, and major access-site or vascular injury requiring surgery was 5.1%. Nobody should toss those numbers around casually; this is a severely ill, high-risk group, and mortality is not a footnote.

What caught my eye was the comparison between delivery-system generations. With the Enhanced Delivery System, major bleeding was reported at 5.0%, down from 21% with the first-generation system. Major vascular complications declined to 3.0% from 8.8%. Device therapies often get their reputation made or broken by the delivery hardware. If those improvements persist as use expands, they could make the procedure more practical for physicians and less punishing for patients.

Approval Is Still a Milestone, Not a Revenue Line

For investors following Venus Medtech, 2500.HK, the next event is regulatory rather than clinical. Cardiovalve is preparing its CE Mark application, and the company expects potential European commercialization in the second half of 2027. That wording is appropriately squishy. Potential is not approval, and approval is not uptake. Hospitals, physician training, reimbursement, manufacturing capacity and competition all get their say after regulators do.

Still, Venus has a broader structural-heart pipeline across all four valves, and Cardiovalve brings more than 150 approved patents into that setup. TARGET does not settle the competitive debate in transcatheter tricuspid replacement. It does give the company a more substantial clinical foundation than a one-year snapshot ever could. The next useful proof will be regulatory progress and evidence that these results travel cleanly from a study cohort into ordinary clinical practice.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 347

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 37

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

Westlake Chemical Partners Schedules Q4 and Year-End Call

Updated Category News Views 158

Westlake Chemical Partners to Announce Earnings Soon Westlake Chemical Partners (NYSE: WLKP), based in Houston, is preparing to release its earnings report for the fourth quarter and full year 2024. This significant announcement is eagerly anticipated by investors and industry analysts alike. The earnings report is scheduled to be released prior to the market opening on a...

Continue Reading
Wabtec's Bold Move: Acquiring Evident's Tech Division

Updated Category News Views 144

Wabtec's Strategic Acquisition of Evident's Inspection Technologies Wabtec Corp, a leader in heavy industrial parts manufacturing, has made headlines with its recent decision to acquire the inspection technologies division of Evident for an impressive $1.78 billion. This acquisition reflects Wabtec's strategy to enhance its portfolio and strengthen its position within the...

Continue Reading
Insight into WisdomTree's Latest Fund Valuations

Updated Category News Views 184

Understanding Net Asset Values in ETFs Investors often seek knowledge about the net asset values (NAVs) of Exchange Traded Funds (ETFs), which play a critical role in determining how funds are valued and traded in the market. For instance, WisdomTree Issuer plc regularly offers updates concerning its funds, revealing the intricate details behind price fluctuations and...

Continue Reading
Investigation Announced Into Electronic Systems Technology, Inc.

Updated Category News Views 239

Investigation of Electronic Systems Technology, Inc. In a noteworthy development, the M&A Class Action Firm has announced an investigation into Electronic Systems Technology, Inc. (OTCMKTS: ELST). This firm, recognized as a top competitor in the 2024 ISS Securities Class Action Services Report, is dedicated to protecting shareholder interests. The firm, led by renowned...

Continue Reading
Fusion CBD Products Partners with Major League Baseball Teams

Updated Category News Views 291

Fusion CBD Products and Major League Baseball: A Growing Partnership Team sponsorship opportunities expand as the league embraces CBD's advantages. As the Major League Baseball (MLB) season unfolds, many players are facing injuries from early training sessions and games. Notable players like Heliot Ramos of the San Francisco Giants and Erik Miller have recently dealt with...

Continue Reading